RevonBio

Revon Bio is a biotechnology company dedicated to developing transformative gene therapies for rare neurodevelopmental and metabolic disorders. The company's primary focus is on Creatine Transporter Deficiency (CTD), a rare X-linked condition caused by mutations in the SLC6A8 gene that leads to intellectual disability, seizures, and speech delays. Revon Bio utilizes an adeno-associated virus (AAV) platform to deliver functional copies of the SLC6A8 gene directly to the central nervous system. Their lead program, RB-101, aims to restore brain creatine levels and address the underlying cause of the disease. The company works closely with patient advocacy groups to accelerate the development of disease-modifying treatments for underserved populations.